TriangleHEALTH PROFESSIONAL · SOURCE READING
Ibrutinib versus zanubrutinib
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (ibrutinib vs. zanubrutinib):
A prospective randomized trial of 652 patients with relapsed or refractory CLL compared ibrutinib and zanubrutinib.[6]
Source links and citations
A prospective randomized trial of 652 patients with relapsed or refractory CLL compared ibrutinib and zanubrutinib.[6]
With a median follow-up of 29.6 months, the 2-year progression-free survival (PFS) rate was 78.4% in the zanubrutinib group and 65.9% in the ibrutinib group (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.49–0.86; P = .002).[6][Level of evidence B1]
Source links and citations
A prospective randomized trial of 652 patients with relapsed or refractory CLL compared ibrutinib and zanubrutinib.[6]
Cardiac disorders leading to treatment discontinuation occurred in 1 patient (0.3%) in the zanubrutinib group and 14 patients (4.3%) in the ibrutinib group. Six deaths caused by cardiac events were all in patients who received ibrutinib.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice